Altimmune Secures $75M in Direct Stock Offering to Advance Liver Disease Treatment
Altimmune raises $75 million through registered direct offering to fund Phase 3 trial of pemvidutide for MASH treatment and advance its liver disease therapy pipeline.
Already have an account? Sign in.